Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Gyre Therapeutics (GYRE) over the last 13 years, with Sep 2025 value amounting to $18.0 million.

  • Gyre Therapeutics' Gains from Investment Securities fell 2.70% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year decrease of 2.70%. This contributed to the annual value of $18.1 million for FY2024, which is 1.11% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Gains from Investment Securities stood at $18.0 million, which was up 1.32% from $17.8 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Gains from Investment Securities ranged from a high of $18.5 million in Q3 2024 and a low of -$2.9 million during Q2 2024.
  • For the 3-year period, Gyre Therapeutics' Gains from Investment Securities averaged around $8.4 million, with its median value being $3.7 million (2023).
  • Data for Gyre Therapeutics' Gains from Investment Securities shows a peak YoY increase of 1,241.94% (in 2024) and a maximum YoY decrease of 182.29% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Gains from Investment Securities stood at $2.6 million in 2021, then soared by 554.35% to $17.0 million in 2022, then crashed by 77.25% to $3.9 million in 2023, then tumbled by 52.45% to $1.8 million in 2024, then fell by 2.70% to $18.0 million in 2025.
  • Its Gains from Investment Securities stands at $18.0 million for Q3 2025, versus $17.8 million for Q2 2025 and $3.4 million for Q1 2025.